Tranexamic acid in trauma is a well-established standard of care in most mature trauma systems. The two major trials of TXA, CRASH 2 and 3 suggest a small but important …
Differential prescribing of TXA by gender. St Emlyn’s Read More »
Our regular podcast round up from February 2021. Iain and Simon highlight the key learning points from this month on the St Emlyn’s blog and podcast. Please remember to subscribe …
Over the years we have had more than a passing interest in tranexamic acid. In part because we have been involved in some of the research, recruiting to trials, or …
JC: The NoPAC trial. TXA does not work for epistaxis. St Emlyn’s Read More »
This post is co-published with our friends at REBEL EM. Background: It almost seems that when it comes to the use of the antifibrinolytic agent tranexamic acid (TXA) in trauma, …
Welcome to our audio round up of everything on the blog during September. It’s been a relatively quiet on the blog post this month, but we chat through not only …
Tranexamic Acid (TXA) is a mainstay of trauma management. CRASH 2 (2) demonstrated its effectiveness in bleeding patients and CRASH 3 (1,5) (in my opinion) showed that we should also …
JC: Can we give tranexamic acid (TXA) via the IM route? St Emlyn’s Read More »
Our post on the CRASH-3 trial, an RCT examining the use of TXA in head injury, was arguably our most controversial of 2019 (1). Our view was that the evidence …
If you’re any kind of emergency care aficionado, you probably worship at the altar of tranexamic acid (TXA). With data showing more favourable outcomes from its use in traumatic bleeding​(1)​, …
JC: Halt! It’s not time for TXA! Or is it? HALT-IT results at St Emlyn’s Read More »
